Yes!  I want to receive ReSPECT-LM Clinical Trial updates for leptomeningeal metastases!

Not ready to sign up yet?

Explore the ReSPECT-LM website here.

Yes! I want to receive ReSPECT-LM Clinical Trial updates for leptomeningeal metastases!

Not ready to sign up?

Explore the ReSPECT-LM website here.

The purpose of the ReSPECT-LM Clinical Trial is to assess the safety and tolerability of an innovative, targeted radiotherapeutic, 186RNL (Rhenium-186 NanoLiposome), in adults with leptomeningeal metastases and to identify a maximum tolerated dose and/or maximum feasible dose.  

Subscribe to Email Alerts

  • Trial Information

  • Patient Eligibility

  • Next Steps

  • News

  • Publications

  • Resources

To opt-in, please complete the form above.